SpecificiT Pharma Inc.

SpecificiT Pharma Inc. is a biotechnology firm specializing in personalized cancer immunotherapies, focusing on innovative cellular therapies for hematological cancers underserved by traditional treatments. SpecificiT Pharma Inc. develops personalized cancer immunotherapies, particularly in cellular therapies targeting hematological cancers.

The company is headquartered in Montreal, Canada, and raised seed funding in September 2017 with participation from Accel-Rx Health Sciences Accelerator, Sanderling Ventures, and returning investor GeneChem. SpecificiT Pharma Inc. specializes in the development of personalized cancer immunotherapies, focusing primarily on cellular therapies for hematological cancers that are not effectively treated with traditional chimeric antigen receptor modified T cell (CAR-T) therapies. The company's innovative approach leverages Minor Histocompatibility Antigens (MiHAs) to facilitate the direction of donor T-cells towards the elimination of cancer cells within patients.

This targeted therapeutic strategy addresses significant unmet medical needs in oncology, specifically for patients suffering from hematological malignancies. The therapies are intended for use by healthcare providers and institutions involved in cancer treatment, primarily in markets such as North America and Europe, where personalized medicine is becoming increasingly prevalent in oncology practices. SpecificiT Pharma operates within a framework that emphasizes strategic partnerships and collaborations with healthcare institutions, researchers, and biotechnology companies for the commercialization of its therapeutic products. Revenue generation is structured around these partnerships, which may include collaborative research agreements, licensing deals, and potential product sales directly to healthcare providers.

The specific pricing plans and transaction structures are designed to reflect the value of the innovative therapies offered, particularly for flagship products that utilize MiHAs for targeted cancer treatment. This approach aligns with the company’s commitment to enhancing patient outcomes while establishing a sustainable financial model in the competitive biopharmaceutical landscape. SpecificiT Pharma Inc. plans to leverage recent funding from its September 2017 seed round to advance the development of new personalized cancer therapies, particularly those targeting hematological malignancies.

The company aims to expand its market presence in North America and Europe by collaborating with additional healthcare providers and institutions. The funding will support research initiatives and potential product launches, enhancing their therapeutic offerings tailored for oncology.